SCHEMBL14616486

SCHEMBL14616486

CCCOCCOCCCNC(=O)[C@@H](N)CCCCN

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GNAI3 P08754 1/20 0.68
▸ GNAO1 P09471 1/20 0.68
▸ GNAI1 P63096 1/20 0.68
▸ DPP7 Q9UHL4 3/20 0.56
▸ TLR2 O60603 5/20 0.56
▸ RRM1 P23921 1/20 0.55
▸ DPP8 Q6V1X1 1/20 0.46
▸ DPP9 Q86TI2 1/20 0.46
▸ SIRT6 Q8N6T7 1/20 0.45
▸ SIRT1 Q96EB6 1/20 0.45
▸ TERT O14746 2/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CHRNA1 P02708 1/20 0.42
▸ CHRNG P07510 1/20 0.42
▸ CHRNB1 P11230 1/20 0.42
▸ CHRND Q07001 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14205322 0.93 GNAI3 (0.65) GNAI3GNAO1GNAI1DPP7TLR2
SCHEMBL30094858 0.93 GNAI3 (0.65) GNAI3GNAO1GNAI1DPP7TLR2
SCHEMBL20980376 0.93 GNAI3 (0.63) GNAI3GNAO1GNAI1DPP7TLR2
SCHEMBL20980426 0.93 GNAI3 (0.63) GNAI3GNAO1GNAI1DPP7TLR2
SCHEMBL24379775 0.93 GNAI3 (0.63) GNAI3GNAO1GNAI1DPP7TLR2
SCHEMBL14616413 0.93 GNAI3 (0.59) GNAI3GNAO1GNAI1DPP7TLR2
SCHEMBL14616487 0.92 GNAI3 (0.63) GNAI3GNAO1GNAI1DPP7TLR2
SCHEMBL14240492 0.91 GNAI3 (0.61) GNAI3GNAO1GNAI1DPP7TLR2
SCHEMBL20980377 0.88 GNAI3 (0.56) GNAI3GNAO1GNAI1DPP7TLR2
SCHEMBL14616462 0.87 GNAI3 (0.59) GNAI3GNAO1GNAI1DPP7TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9393315-B2 Compounds for targeting drug delivery and enhancing siRNA activity NITTO DENKO CORPORATION (JP) 2016-07-19 — — US disclosed
US-9393315-B2 Compounds for targeting drug delivery and enhancing siRNA activity NITTO DENKO CORPORATION (JP) 2016-07-19 — — US disclosed
US-20130017249-A1 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY NITTO DENKO CORPORATION (JP) 2013-01-17 — — US disclosed
US-20130017249-A1 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY NITTO DENKO CORPORATION (JP) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130017249-A1 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY LDLR, RARG, FABP4 GNAI3 3017/4885GNAO1 3483/4885GNAI1 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback